Literature DB >> 19031229

Genetics of aminoglycoside-induced and prelingual non-syndromic mitochondrial hearing impairment: a review.

L Hema Bindu1, P P Reddy.   

Abstract

Pathogenic mitochondrial DNA mutations are most often implicated in inherited and acquired hearing impairment. The current review mainly focuses on the 12S rRNA mitochondrial gene mutations associated with non-syndromic deafness without or after aminoglycosides exposure. Aminoglycoside-induced and nonsyndromic deafness has been shown to have a genetic susceptibility and the pathogenic mitochondrial 12S rRNA A1555G mutation was identified as the primary factor underlying the hearing loss in many familial as well as in genetically unrelated cases, particularly in Asian populations where aminoglycoside antibiotics are commonly used even for minor infections. Many families were shown to transmit the aminoglycoside ototoxicity through matrilineal inheritance and the A1555G mutation in the 12S rRNA gene was frequently identified. The aminoglycoside antibiotics are believed to target the mitochondrial ribosome in the cochlea resulting in abnormal RNA processing or decreased efficiency of translation thereby leading to irreversible auditory dysfunction. Such cases may have a genetic predisposition to aminoglycoside ototoxicity following autosomal dominant, autosomal recessive, X-linked, or mitochondrial pattern of inheritance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19031229     DOI: 10.1080/14992020802215862

Source DB:  PubMed          Journal:  Int J Audiol        ISSN: 1499-2027            Impact factor:   2.117


  24 in total

Review 1.  Drug-Induced Ototoxicity: Diagnosis and Monitoring.

Authors:  Kathleen C M Campbell; Colleen G Le Prell
Journal:  Drug Saf       Date:  2018-05       Impact factor: 5.606

2.  ER-mitochondrial calcium flow underlies vulnerability of mechanosensory hair cells to damage.

Authors:  Robert Esterberg; Dale W Hailey; Edwin W Rubel; David W Raible
Journal:  J Neurosci       Date:  2014-07-16       Impact factor: 6.167

3.  Screening for the mitochondrial A1555G mutation among Egyptian patients with non-syndromic, sensorineural hearing loss.

Authors:  Mahmoud R Fassad; Lubna M Desouky; Samir Asal; Ebtesam M Abdalla
Journal:  Int J Mol Epidemiol Genet       Date:  2014-12-15

4.  Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis.

Authors:  Amber Arnold; Graham S Cooke; Onn Min Kon; Martin Dedicoat; Marc Lipman; Angela Loyse; Irina Chis Ster; Thomas S Harrison
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

5.  A genome-wide analysis of targets of macrolide antibiotics in mammalian cells.

Authors:  Amita Gupta; Aye Ökesli-Armlovich; David Morgens; Michael C Bassik; Chaitan Khosla
Journal:  J Biol Chem       Date:  2020-01-08       Impact factor: 5.157

Review 6.  The challenge of hair cell regeneration.

Authors:  Andrew K Groves
Journal:  Exp Biol Med (Maywood)       Date:  2010-04

7.  Small molecule screening in zebrafish: an in vivo approach to identifying new chemical tools and drug leads.

Authors:  Kerrie L Taylor; Nicola J Grant; Nicholas D Temperley; E Elizabeth Patton
Journal:  Cell Commun Signal       Date:  2010-06-12       Impact factor: 5.712

8.  Effect of streptomycin on melanogenesis and antioxidant status in melanocytes.

Authors:  Dorota Wrześniok; Artur Beberok; Michał Otręba; Ewa Buszman
Journal:  Mol Cell Biochem       Date:  2013-07-19       Impact factor: 3.396

9.  A modern approach to the treatment of mitochondrial disease.

Authors:  Sumit Parikh; Russell Saneto; Marni J Falk; Irina Anselm; Bruce H Cohen; Richard Haas; The Mitochondrial Medicine Society
Journal:  Curr Treat Options Neurol       Date:  2009-11       Impact factor: 3.598

10.  Assessment of nutrient supplement to reduce gentamicin-induced ototoxicity.

Authors:  C G Le Prell; C Ojano-Dirain; E W Rudnick; M A Nelson; S J DeRemer; D M Prieskorn; J M Miller
Journal:  J Assoc Res Otolaryngol       Date:  2014-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.